The systemic aspergillosis and systemic candidiasis market size has grown steadily in recent years. It will grow from $7.57 billion in 2025 to $7.94 billion in 2026 at a compound annual growth rate (CAGR) of 4.9%. The growth in the historic period can be attributed to increasing immunocompromised patient populations, rising prevalence of invasive fungal infections, availability of azole and amphotericin formulations, expansion of hospital intensive care units, improved diagnostic awareness.
The systemic aspergillosis and systemic candidiasis market size is expected to see strong growth in the next few years. It will grow to $9.76 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to increasing development of novel antifungal agents, rising focus on antifungal resistance management, expansion of targeted antifungal therapies, growing investments in infectious disease research, increasing adoption of combination treatment regimens. Major trends in the forecast period include increasing adoption of advanced antifungal therapies, rising focus on early diagnosis of systemic fungal infections, expansion of combination antifungal treatment approaches, growing demand for hospital-based critical care antifungals, enhanced monitoring of drug resistance patterns.
The rising incidence of fungal diseases is expected to drive the growth of the systemic aspergillosis and systemic candidiasis market in the coming years. Fungal diseases are infections caused by fungi that can affect various parts of the body, leading to a range of symptoms and complications. These infections include skin infections, respiratory infections, and systemic infections. Antifungal medications, such as oral azoles, voriconazole, and liposomal amphotericin B, are commonly used to treat these conditions. For example, in 2023, according to the UK Health Security Agency, a UK-based government body, the rate of yeast-related bloodstream infections across England increased by 4% compared to 2022. Therefore, the growing prevalence of fungal diseases is propelling the systemic aspergillosis and systemic candidiasis market.
Leading companies in the systemic aspergillosis and systemic candidiasis markets are focusing on developing advanced treatments, such as echinocandins, to improve therapeutic efficacy and address the increasing challenge of antifungal resistance. Echinocandins are a class of antifungal drugs that inhibit β-glucan synthesis, an essential component of the fungal cell wall. For instance, in March 2023, Cidara Therapeutics, a US-based biotechnology company, and Melinta Therapeutics, also US-based, received FDA approval for REZZAYO (rezafungin for injection). REZZAYO is a novel once-weekly echinocandin indicated for the treatment of candidemia in adults with limited or no alternative options. Its once-weekly dosing simplifies administration and improves continuity of care, particularly in hospital settings, where effective management of invasive candidiasis is critical.
In August 2023, Sandoz, a Germany-based global pharmaceutical company, acquired Astellas Pharma Inc. for an undisclosed amount. Through this acquisition, Sandoz aims to strengthen its hospital offerings and expand its anti-infectives portfolio, providing essential antimicrobial therapies and supporting responsible use through targeted treatments for patients in need. Astellas Pharma Inc. is a Japan-based pharmaceutical company that develops therapies for systemic aspergillosis and systemic candidiasis.
Major companies operating in the systemic aspergillosis and systemic candidiasis market are Pfizer Inc, Merck & Co. Inc, AbbVie Inc, Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Abbott Laboratories, Sanofi S.A, GlaxoSmithKline PLC, Gilead Sciences Inc, Astellas Pharma Inc, Matinas BioPharma Holdings Inc, Shionogi & Co. Ltd, Cipla Limited, Basilea Pharmaceutica Ltd, Cidara Therapeutics Inc, Entasis Therapeutics Inc, F2G Ltd, Mycovia Pharmaceuticals Inc, ContraFect Corporation, Enzon Pharmaceutical Inc, Pacgen Life Science Corporation, Biosergen AS.
North America was the largest region in the systemic aspergillosis and systemic candidiasis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the systemic aspergillosis and systemic candidiasis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the systemic aspergillosis and systemic candidiasis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the systemic aspergillosis and systemic candidiasis market by increasing costs of imported active pharmaceutical ingredients, sterile injectables, formulation equipment, and specialized packaging materials. Hospitals and pharmaceutical manufacturers in North America and Europe are most affected due to reliance on imported APIs, while Asia-Pacific faces cost pressure on export-oriented antifungal production. These tariffs are increasing treatment costs and supply chain complexity. However, they are also encouraging domestic API manufacturing, regional drug formulation, and improved supply security for critical antifungal medications.
The systemic aspergillosis and systemic candidiasis market research report is one of a series of new reports that provides systemic aspergillosis and systemic candidiasis market statistics, including systemic aspergillosis and systemic candidiasis industry global market size, regional shares, competitors with a systemic aspergillosis and systemic candidiasis market share, detailed systemic aspergillosis and systemic candidiasis market segments, market trends and opportunities, and any further data you may need to thrive in the systemic aspergillosis and systemic candidiasis industry. This systemic aspergillosis and systemic candidiasis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Systemic aspergillosis is the most severe form of aspergillosis, occurring when the infection spreads beyond the lungs to other organs. Systemic candidiasis refers to a range of yeast infections caused by different Candida species. Both systemic aspergillosis and systemic candidiasis are serious conditions that can affect the blood, heart, brain, eyes, bones, and other organs.
The main types of treatments for systemic aspergillosis and systemic candidiasis include systemic oral azoles, voriconazole, liposomal amphotericin B, topical antifungal agents, and others. Systemic oral azoles are antifungal medications taken orally to treat systemic fungal infections throughout the body. They work by targeting specific enzymes essential for fungal survival, thereby inhibiting the growth and replication of fungal cells. These treatments are used for conditions such as allergic bronchopulmonary aspergillosis (ABPA), chronic pulmonary aspergillosis (CPA), gastrointestinal candidiasis, genitourinary tract candidiasis, and more, and are administered by hospitals, clinics, and other healthcare providers.
The systemic aspergillosis and systemic candidiasis market consists of sales of voriconazole and amphotericin B. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The systemic aspergillosis and systemic candidiasis market size is expected to see strong growth in the next few years. It will grow to $9.76 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to increasing development of novel antifungal agents, rising focus on antifungal resistance management, expansion of targeted antifungal therapies, growing investments in infectious disease research, increasing adoption of combination treatment regimens. Major trends in the forecast period include increasing adoption of advanced antifungal therapies, rising focus on early diagnosis of systemic fungal infections, expansion of combination antifungal treatment approaches, growing demand for hospital-based critical care antifungals, enhanced monitoring of drug resistance patterns.
The rising incidence of fungal diseases is expected to drive the growth of the systemic aspergillosis and systemic candidiasis market in the coming years. Fungal diseases are infections caused by fungi that can affect various parts of the body, leading to a range of symptoms and complications. These infections include skin infections, respiratory infections, and systemic infections. Antifungal medications, such as oral azoles, voriconazole, and liposomal amphotericin B, are commonly used to treat these conditions. For example, in 2023, according to the UK Health Security Agency, a UK-based government body, the rate of yeast-related bloodstream infections across England increased by 4% compared to 2022. Therefore, the growing prevalence of fungal diseases is propelling the systemic aspergillosis and systemic candidiasis market.
Leading companies in the systemic aspergillosis and systemic candidiasis markets are focusing on developing advanced treatments, such as echinocandins, to improve therapeutic efficacy and address the increasing challenge of antifungal resistance. Echinocandins are a class of antifungal drugs that inhibit β-glucan synthesis, an essential component of the fungal cell wall. For instance, in March 2023, Cidara Therapeutics, a US-based biotechnology company, and Melinta Therapeutics, also US-based, received FDA approval for REZZAYO (rezafungin for injection). REZZAYO is a novel once-weekly echinocandin indicated for the treatment of candidemia in adults with limited or no alternative options. Its once-weekly dosing simplifies administration and improves continuity of care, particularly in hospital settings, where effective management of invasive candidiasis is critical.
In August 2023, Sandoz, a Germany-based global pharmaceutical company, acquired Astellas Pharma Inc. for an undisclosed amount. Through this acquisition, Sandoz aims to strengthen its hospital offerings and expand its anti-infectives portfolio, providing essential antimicrobial therapies and supporting responsible use through targeted treatments for patients in need. Astellas Pharma Inc. is a Japan-based pharmaceutical company that develops therapies for systemic aspergillosis and systemic candidiasis.
Major companies operating in the systemic aspergillosis and systemic candidiasis market are Pfizer Inc, Merck & Co. Inc, AbbVie Inc, Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Abbott Laboratories, Sanofi S.A, GlaxoSmithKline PLC, Gilead Sciences Inc, Astellas Pharma Inc, Matinas BioPharma Holdings Inc, Shionogi & Co. Ltd, Cipla Limited, Basilea Pharmaceutica Ltd, Cidara Therapeutics Inc, Entasis Therapeutics Inc, F2G Ltd, Mycovia Pharmaceuticals Inc, ContraFect Corporation, Enzon Pharmaceutical Inc, Pacgen Life Science Corporation, Biosergen AS.
North America was the largest region in the systemic aspergillosis and systemic candidiasis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the systemic aspergillosis and systemic candidiasis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the systemic aspergillosis and systemic candidiasis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the systemic aspergillosis and systemic candidiasis market by increasing costs of imported active pharmaceutical ingredients, sterile injectables, formulation equipment, and specialized packaging materials. Hospitals and pharmaceutical manufacturers in North America and Europe are most affected due to reliance on imported APIs, while Asia-Pacific faces cost pressure on export-oriented antifungal production. These tariffs are increasing treatment costs and supply chain complexity. However, they are also encouraging domestic API manufacturing, regional drug formulation, and improved supply security for critical antifungal medications.
The systemic aspergillosis and systemic candidiasis market research report is one of a series of new reports that provides systemic aspergillosis and systemic candidiasis market statistics, including systemic aspergillosis and systemic candidiasis industry global market size, regional shares, competitors with a systemic aspergillosis and systemic candidiasis market share, detailed systemic aspergillosis and systemic candidiasis market segments, market trends and opportunities, and any further data you may need to thrive in the systemic aspergillosis and systemic candidiasis industry. This systemic aspergillosis and systemic candidiasis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Systemic aspergillosis is the most severe form of aspergillosis, occurring when the infection spreads beyond the lungs to other organs. Systemic candidiasis refers to a range of yeast infections caused by different Candida species. Both systemic aspergillosis and systemic candidiasis are serious conditions that can affect the blood, heart, brain, eyes, bones, and other organs.
The main types of treatments for systemic aspergillosis and systemic candidiasis include systemic oral azoles, voriconazole, liposomal amphotericin B, topical antifungal agents, and others. Systemic oral azoles are antifungal medications taken orally to treat systemic fungal infections throughout the body. They work by targeting specific enzymes essential for fungal survival, thereby inhibiting the growth and replication of fungal cells. These treatments are used for conditions such as allergic bronchopulmonary aspergillosis (ABPA), chronic pulmonary aspergillosis (CPA), gastrointestinal candidiasis, genitourinary tract candidiasis, and more, and are administered by hospitals, clinics, and other healthcare providers.
The systemic aspergillosis and systemic candidiasis market consists of sales of voriconazole and amphotericin B. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Systemic Aspergillosis and Systemic Candidiasis Market Characteristics
3. Systemic Aspergillosis and Systemic Candidiasis Market Supply Chain Analysis
4. Global Systemic Aspergillosis and Systemic Candidiasis Market Trends and Strategies
5. Systemic Aspergillosis and Systemic Candidiasis Market Analysis of End Use Industries
7. Global Systemic Aspergillosis and Systemic Candidiasis Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Systemic Aspergillosis and Systemic Candidiasis Total Addressable Market (TAM) Analysis for the Market
9. Systemic Aspergillosis and Systemic Candidiasis Market Segmentation
10. Systemic Aspergillosis and Systemic Candidiasis Market Regional and Country Analysis
11. Asia-Pacific Systemic Aspergillosis and Systemic Candidiasis Market
12. China Systemic Aspergillosis and Systemic Candidiasis Market
13. India Systemic Aspergillosis and Systemic Candidiasis Market
14. Japan Systemic Aspergillosis and Systemic Candidiasis Market
15. Australia Systemic Aspergillosis and Systemic Candidiasis Market
16. Indonesia Systemic Aspergillosis and Systemic Candidiasis Market
17. South Korea Systemic Aspergillosis and Systemic Candidiasis Market
18. Taiwan Systemic Aspergillosis and Systemic Candidiasis Market
19. South East Asia Systemic Aspergillosis and Systemic Candidiasis Market
20. Western Europe Systemic Aspergillosis and Systemic Candidiasis Market
21. UK Systemic Aspergillosis and Systemic Candidiasis Market
22. Germany Systemic Aspergillosis and Systemic Candidiasis Market
23. France Systemic Aspergillosis and Systemic Candidiasis Market
24. Italy Systemic Aspergillosis and Systemic Candidiasis Market
25. Spain Systemic Aspergillosis and Systemic Candidiasis Market
26. Eastern Europe Systemic Aspergillosis and Systemic Candidiasis Market
27. Russia Systemic Aspergillosis and Systemic Candidiasis Market
28. North America Systemic Aspergillosis and Systemic Candidiasis Market
29. USA Systemic Aspergillosis and Systemic Candidiasis Market
30. Canada Systemic Aspergillosis and Systemic Candidiasis Market
31. South America Systemic Aspergillosis and Systemic Candidiasis Market
32. Brazil Systemic Aspergillosis and Systemic Candidiasis Market
33. Middle East Systemic Aspergillosis and Systemic Candidiasis Market
34. Africa Systemic Aspergillosis and Systemic Candidiasis Market
36. Systemic Aspergillosis and Systemic Candidiasis Market Competitive Landscape and Company Profiles
37. Systemic Aspergillosis and Systemic Candidiasis Market Other Major and Innovative Companies
40. Systemic Aspergillosis and Systemic Candidiasis Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Systemic Aspergillosis And Systemic Candidiasis Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses systemic aspergillosis and systemic candidiasis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for systemic aspergillosis and systemic candidiasis? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The systemic aspergillosis and systemic candidiasis market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Systemic Oral Azoles; Voriconazole; Liposomal Amphotericin B; Topical Antifungal Agents; Other Types2) By Application: Allergic Bronchopulmonary Aspergillosis (ABPA); Chronic Pulmonary Aspergillosis (CPA); Gastrointestinal Candidiasis; Genitourinary Tract Candidiasis; Other Applications
3) By End User: Clinic; Hospital; Other End Users
Subsegments:
1) By Systemic Oral Azoles: Fluconazole; Itraconazole; Posaconazole; Voriconazole2) By Voriconazole: Voriconazole Tablets; Voriconazole Injection
3) By Liposomal Amphotericin B: Liposomal Amphotericin B For Systemic Aspergillosis; Liposomal Amphotericin B For Systemic Candidiasis
4) By Topical Antifungal Agents: Topical Azoles; Topical Polyenes; Topical Allylamines
5) By Other Types: Echinocandins; Antifungal Combination Therapies; Other Emerging Antifungal Agents
Companies Mentioned: Pfizer Inc; Merck & Co. Inc; AbbVie Inc; Bayer AG; Novartis AG; Bristol-Myers Squibb Company; Abbott Laboratories; Sanofi S.A; GlaxoSmithKline PLC; Gilead Sciences Inc; Astellas Pharma Inc; Matinas BioPharma Holdings Inc; Shionogi & Co. Ltd; Cipla Limited; Basilea Pharmaceutica Ltd; Cidara Therapeutics Inc; Entasis Therapeutics Inc; F2G Ltd; Mycovia Pharmaceuticals Inc; ContraFect Corporation; Enzon Pharmaceutical Inc; Pacgen Life Science Corporation; Biosergen AS
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Systemic Aspergillosis and Systemic Candidiasis market report include:- Pfizer Inc
- Merck & Co. Inc
- AbbVie Inc
- Bayer AG
- Novartis AG
- Bristol-Myers Squibb Company
- Abbott Laboratories
- Sanofi S.A
- GlaxoSmithKline PLC
- Gilead Sciences Inc
- Astellas Pharma Inc
- Matinas BioPharma Holdings Inc
- Shionogi & Co. Ltd
- Cipla Limited
- Basilea Pharmaceutica Ltd
- Cidara Therapeutics Inc
- Entasis Therapeutics Inc
- F2G Ltd
- Mycovia Pharmaceuticals Inc
- ContraFect Corporation
- Enzon Pharmaceutical Inc
- Pacgen Life Science Corporation
- Biosergen AS
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 7.94 Billion |
| Forecasted Market Value ( USD | $ 9.76 Billion |
| Compound Annual Growth Rate | 5.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 23 |
